A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation

CONCLUSIONS: Prophylactic use of oral acyclovir effectively reduced the incidence of CIOM in patients with HM who were undergoing AHSCT.TRIAL REGISTRATIONS: This trial was registered at the Clinical Research Information Service in the Republic of Korea under the number KCT0003885 (registration date 03/05/2019).PMID:38102638 | DOI:10.1186/s12903-023-03623-6

Source: Herpes - December 15, 2023 Category: Infectious Diseases Authors: Junshik Hong Hee-Kyung Park Sung-Ho Chang Ja Min Byun Dong-Yeop Shin Youngil Koh Sung-Soo Yoon Youngnim Choi Inho Kim Source Type: research